AU2014326298B2 - Prostaglandin F2alpha and analogues thereof for treating atrophic cutaneous scarring - Google Patents

Prostaglandin F2alpha and analogues thereof for treating atrophic cutaneous scarring Download PDF

Info

Publication number
AU2014326298B2
AU2014326298B2 AU2014326298A AU2014326298A AU2014326298B2 AU 2014326298 B2 AU2014326298 B2 AU 2014326298B2 AU 2014326298 A AU2014326298 A AU 2014326298A AU 2014326298 A AU2014326298 A AU 2014326298A AU 2014326298 B2 AU2014326298 B2 AU 2014326298B2
Authority
AU
Australia
Prior art keywords
pgf
atrophic
alpha
pharmaceutical composition
scarring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2014326298A
Other languages
English (en)
Other versions
AU2014326298A1 (en
Inventor
Warren J. Scherer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Galderma Holding SA
Original Assignee
Galderma Holding SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galderma Holding SA filed Critical Galderma Holding SA
Publication of AU2014326298A1 publication Critical patent/AU2014326298A1/en
Application granted granted Critical
Publication of AU2014326298B2 publication Critical patent/AU2014326298B2/en
Assigned to Galderma Holding SA reassignment Galderma Holding SA Request for Assignment Assignors: GALDERMA S.A.
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Dispersion Chemistry (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • External Artificial Organs (AREA)
AU2014326298A 2013-09-26 2014-09-26 Prostaglandin F2alpha and analogues thereof for treating atrophic cutaneous scarring Ceased AU2014326298B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361960740P 2013-09-26 2013-09-26
US61/960,740 2013-09-26
PCT/IB2014/002746 WO2015044788A1 (en) 2013-09-26 2014-09-26 Prostaglandin f2alpha and analogues thereof for treating atrophic cutaneous scarring

Publications (2)

Publication Number Publication Date
AU2014326298A1 AU2014326298A1 (en) 2016-04-07
AU2014326298B2 true AU2014326298B2 (en) 2019-07-04

Family

ID=52282772

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2014326298A Ceased AU2014326298B2 (en) 2013-09-26 2014-09-26 Prostaglandin F2alpha and analogues thereof for treating atrophic cutaneous scarring

Country Status (11)

Country Link
US (1) US10039770B2 (enExample)
EP (1) EP3049088B1 (enExample)
JP (1) JP6453318B2 (enExample)
KR (1) KR102221499B1 (enExample)
CN (1) CN105658221B (enExample)
AU (1) AU2014326298B2 (enExample)
BR (1) BR112016006426A2 (enExample)
CA (1) CA2924460A1 (enExample)
MX (1) MX374476B (enExample)
RU (1) RU2690183C2 (enExample)
WO (1) WO2015044788A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3319607A4 (en) * 2015-07-09 2019-04-03 Galderma S.A. METHOD FOR REDUCING HAIR LOSS IN CONNECTION WITH CHEMOTHERAPY
CN106929477B (zh) * 2017-03-20 2020-01-10 江南大学 一株抗前列腺素F2α的特异性单克隆抗体杂交瘤细胞株WXX-2及其应用
KR20240004954A (ko) * 2021-05-07 2024-01-11 바치바이오메드 인크. 소분자 화합물을 사용하여 여드름-후 위축성 흉터의 외관을 개선하는 방법 (methods of using a small molecule chemical compound to reduce the appearance of post-acne atrophic scarring)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120251613A1 (en) * 2011-03-29 2012-10-04 Agila Specialities Pvt. Ltd. Method for treating vitiligo with a prostaglandin analogue

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3278447A (en) 1963-12-02 1966-10-11 Cloro Bac Products Inc Process for stabilizing chlorine dioxide solution
CA2003198C (en) 1988-11-29 1995-03-21 Anthony J. Dziabo, Jr. Aqueous ophthalmic solutions and method for preserving same
US5736165A (en) 1993-05-25 1998-04-07 Allergan In-the-eye use of chlorine dioxide-containing compositions
US6194415B1 (en) 1995-06-28 2001-02-27 Allergan Sales, Inc. Method of using (2-imidazolin-2-ylamino) quinoxoalines in treating neural injury
RU2195889C2 (ru) * 1999-05-24 2003-01-10 Парамонов Борис Алексеевич Способ дермабразии
US6468989B1 (en) 2000-07-13 2002-10-22 Dow Pharmaceutical Sciences Gel compositions containing metronidazole
US6387383B1 (en) 2000-08-03 2002-05-14 Dow Pharmaceutical Sciences Topical low-viscosity gel composition
US7405274B2 (en) * 2003-06-04 2008-07-29 Fibrogen, Inc. Connective tissue growth factor antibodies
AU2009246333B2 (en) * 2008-05-16 2013-05-09 Corthera, Inc. Method of promoting wound healing
EP2389939A1 (en) * 2010-05-28 2011-11-30 Novagali Pharma S.A. Use of prostaglandins F2alpha and analogues for the healing of corneal and conjunctival lesions
CN102031260A (zh) * 2010-08-24 2011-04-27 苏州圣诺生物医药技术有限公司 促进皮肤伤口无疤痕愈合的siRNA及应用
JP2014500275A (ja) * 2010-12-06 2014-01-09 フォリカ，インコーポレイテッド 禿頭症を治療するため、および毛髪の成長を促進するための方法
BR112013019519A2 (pt) * 2011-01-31 2016-08-09 Allergan Inc método de realce de crescimento capilar
WO2014179263A1 (en) * 2013-04-30 2014-11-06 Allergan, Inc. Therapeutic agents

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120251613A1 (en) * 2011-03-29 2012-10-04 Agila Specialities Pvt. Ltd. Method for treating vitiligo with a prostaglandin analogue

Also Published As

Publication number Publication date
US10039770B2 (en) 2018-08-07
AU2014326298A1 (en) 2016-04-07
RU2690183C2 (ru) 2019-05-31
RU2016110925A3 (enExample) 2018-07-13
EP3049088B1 (en) 2021-02-17
BR112016006426A2 (pt) 2017-08-01
CA2924460A1 (en) 2015-04-02
EP3049088A1 (en) 2016-08-03
KR20160055941A (ko) 2016-05-18
JP6453318B2 (ja) 2019-01-16
US20160228453A1 (en) 2016-08-11
JP2016531872A (ja) 2016-10-13
MX374476B (es) 2025-03-06
MX2016003650A (es) 2016-06-24
CN105658221B (zh) 2022-05-10
RU2016110925A (ru) 2017-11-01
KR102221499B1 (ko) 2021-03-02
WO2015044788A1 (en) 2015-04-02
CN105658221A (zh) 2016-06-08

Similar Documents

Publication Publication Date Title
AU2008341112B2 (en) Pre-surgical treatment
JP6966455B2 (ja) 侵襲的且つ非侵襲的な処置上のスキンケアのための組成物及び方法
US20120295914A1 (en) Combination of adrenergic receptor agonist alpha-1 or alpha-2, preferably brimonidine with fillers, preferably hyaluronic acid
KR102527685B1 (ko) 주사용 필러 및 콜라겐 성장을 위한 스캐폴드로 유용한 실리콘 수중유형 조성물
JP7421558B2 (ja) 組織修復に適用されるピルフェニドンを含有する半固体油性医薬組成物
US20200012989A1 (en) Compositions and methods for treating cutaneous conditions
EP3049088B1 (en) Prostaglandin f2alpha and analogues thereof for treating atrophic cutaneous scarring
US5520919A (en) Vitamin A palmitate composition and methodology for repairing and rejuvenating human skin
JP2014518239A (ja) 皮膚反応を低減するための新規な安定麻酔組成物
AU2012324544B2 (en) Method for treating capillary hemangiomas
JP2016518409A (ja) 組織外傷の治療のためのαアドレナリン作動薬
US20190000936A1 (en) Prophylactic normalization of cutaneous wound repair
Colom Scar Care after Surgical Treatment in Oncology Patients
WO2025208042A1 (en) Silk peptides topical formulations and methods of their use
KR101796566B1 (ko) 냉감용 흉터 개선 조성물

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: GALDERMA HOLDING SA

Free format text: FORMER OWNER(S): GALDERMA S.A.

MK14 Patent ceased section 143(a) (annual fees not paid) or expired